Respiratory and immune
Published human trials in respiratory infection, from the 1970s trials onward.
This page lists published studies. It reports what the authors did and found, with the limits of each study. It is not advice.
10 studies listed, newest first.
- Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivorsObservational studyHumans
- The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis—A Double-Blind Placebo-Controlled TrialRandomised controlled trialHumans
- What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life SettingObservational studyHumansWith luteolin
- The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection—A Double Blind, Randomised, Placebo-Controlled TrialRandomised controlled trialHumans
- Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndromeRandomised controlled trialHumansWith luteolin
- Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control StudyControlled trialHumans
- Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled TrialRandomised controlled trialHumans
- The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort StudyObservational studyHumans
- Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patientsReviewHumansOther animals
- Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common ColdReviewHumans